Povetacicept
Productby Vera Therapeutics
Heard in 2 episodes across 1 show since Oct 2026
Povetacicept is an investigational dual inhibitor of BLyS and APRIL being developed for autoimmune and immune-mediated diseases.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
| Nov 2026 | 1 |
Email alert
Email me when Povetacicept comes up on a podcast
One email a week at most, with the new episodes that mention Povetacicept. Free, no account needed, unsubscribe in one click.
What experts have said about Povetacicept
4 statements · 1 positive · 2 negative · 1 neutral
Vertex’s povetacicept will likely receive approval.
“I think there's very little doubt. that this drug is going to get approved.”
Open the episode · Episode 202 - November 6, 2026Listen at 16:56
Vertex has declined to disclose treatment interruptions in its study.
“Vertex has not provided that answer. They've declined. to provide an answer.”
Open the episode · Episode 202 - November 6, 2026Listen at 18:35
Vertex’s phase three study showed equal infection risk between treatment and control.
“the infection risk was equal, same between the drug arm and the control arm.”
Open the episode · Episode 202 - November 6, 2026Listen at 18:51
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Povetacicept, newest first
